ApprovedFDA approval

Sunharbo (asundexian)

Bayer HealthCare Pharmaceuticals

Marketer take

Opens a new drug class in secondary stroke prevention, so neurology and cardiology brand teams should expect new HCP education needs and competitive messaging around antiplatelet regimens.

Sponsor company
Bayer HealthCare Pharmaceuticals
Indication
To reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack
Therapeutic area
Cardiovascular, Neurology
Event
FDA approval
Date
Nov 9, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move